IRADIMED CORPORATION to Hold Fourth Quarter and Full Year 2025 Financial Results Conference Call on February 10, 2026
Rhea-AI Summary
IRADIMED (NASDAQ: IRMD) will release its 2025 fourth quarter and full year financial results before the market opens on Tuesday, February 10, 2026.
Company management will host a conference call the same day at 11:00 a.m. Eastern Time, available by registration for dial-in details and via a real-time webcast. A recording will be posted on the investor website after the call.
Positive
- None.
Negative
- None.
News Market Reaction – IRMD
On the day this news was published, IRMD gained 0.74%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
IRMD was down 1.03% pre-announcement, while peers were mixed: TNDM -3.43%, INMD -4.16%, IART -3.32%, ESTA +0.52%, BBNX +3.73%. No unified sector move indicated.
Previous Conferences,earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Oct 27 | Earnings call notice | Neutral | +2.6% | Scheduled Q3 2025 results release and conference call with registration details. |
| Jul 25 | Earnings call notice | Neutral | +1.4% | Announced Q2 2025 results timing and 11:00 a.m. Eastern conference call. |
| Apr 28 | Earnings call notice | Neutral | -0.6% | Outlined corrected Q1 2025 results date and 9:00 a.m. call schedule. |
| Apr 28 | Earnings call notice | Neutral | -0.6% | Initial Q1 2025 results and conference call timing with registration link. |
| Jan 30 | Earnings call notice | Neutral | +0.8% | Set Q4 and full-year 2024 results release and 11:00 a.m. conference call. |
Similar conference-call scheduling announcements have historically led to modest, mixed price moves clustered within a few percent of unchanged.
Over the last year, IRMD has repeatedly announced quarterly and annual financial results calls, typically releasing numbers before the market opens and hosting investor Q&A later that morning. Prior conference-call notices on Jan 30, 2025, Apr 28, 2025, Jul 25, 2025, and Oct 27, 2025 produced relatively small moves, with an average reaction of about 0.74%. Today’s announcement fits this established communication pattern around earnings timing and access details.
Historical Comparison
In the past year, IRMD issued 5 similar earnings call notices. Average move was about 0.74%, suggesting that such scheduling updates have historically driven only modest price shifts.
The company has maintained a consistent pattern of pre-market earnings releases followed by same-day conference calls, reinforcing a regular quarterly communication cadence with investors.
Market Pulse Summary
This announcement sets expectations for the release of Q4 and full-year 2025 results and the related conference call on February 10, 2026. It continues a consistent pattern of pre-market releases followed by detailed management Q&A. In context of prior record Q3 2025 revenue of $21.2M, strong margins of 78%, and raised 2025 guidance, investors may focus on how upcoming results compare to those benchmarks and on any updates to outlook or capital allocation.
AI-generated analysis. Not financial advice.
ORLANDO, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 fourth quarter and full year financial results before the market opens on Tuesday, February 10, 2026. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.
Individuals interested in participating in the conference call may do so by registering here, https://register-conf.media-server.com/register/BI9eabdb5f5ea54652b0bd15ed7530706e. Once registered, a dial-in number, unique pin, and instructions will be provided to participants.
The conference call will also be available real-time via the internet at http://www.iradimed.com/en-us/investors/events/. A recording of the call will be available on the Company’s website following the completion of the call.
About IRADIMED CORPORATION
IRADIMED CORPORATION is a leader in the development of innovative magnetic resonance imaging (“MRI”) compatible medical devices. We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system that is specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components which can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe and dependable fluid delivery before, during and after an MRI scan, which is important to critically ill patients who cannot be removed from their vital medications, and children and infants who must generally be sedated to remain immobile during an MRI scan.
Our 3880 MRI compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The Iradimed 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually anywhere in the MRI scanner room. The Iradimed 3880 has a compact, lightweight design allowing it to travel with the patient from their critical care unit, to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the Iradimed 3880 include: wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and; optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The Iradimed 3880 MRI compatible patient vital signs monitoring system has an easy-to-use design and allows for the effective communication of patient vital signs information to clinicians.
Please visit www.iradimed.com for more information.
Media Contact:
John Glenn
Chief Financial Officer
IRADIMED CORPORATION
(407) 677-8022
InvestorRelations@iradimed.com
FAQ
When will IRADIMED (IRMD) release Q4 and full year 2025 results?
What time is the IRADIMED (IRMD) earnings conference call on February 10, 2026?
How can investors register for the IRADIMED (IRMD) February 10, 2026 conference call?
Will IRADIMED (IRMD) provide a webcast and recording of the February 10, 2026 call?
What topics will IRADIMED (IRMD) management cover on the February 10, 2026 call?
Where can I find the IRADIMED (IRMD) conference call webcast link and replay?
